相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
Minah Kim et al.
FRONTIERS IN IMMUNOLOGY (2021)
Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer
Martina Mandarano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
Kai Tang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Immunotherapy for Glioblastoma: Current Progress and Challenge
Miranda W. Yu et al.
FRONTIERS IN IMMUNOLOGY (2021)
Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma
Lijie Zhai et al.
CLINICAL CANCER RESEARCH (2021)
Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway
Masaru Tanaka et al.
BIOMEDICINES (2021)
Increased effect of two-fraction radiotherapy in conjunction with IDO1 inhibition in experimental glioblastoma
Jonatan Ahlstedt et al.
PLOS ONE (2020)
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
Andrea Botticelli et al.
FRONTIERS IN IMMUNOLOGY (2020)
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+and CD4+T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
Souvik Dey et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment
Tsubasa Miyazaki et al.
CANCERS (2020)
IDO Expression in Cancer: Different Compartment, Different Functionality?
Annabel Meireson et al.
FRONTIERS IN IMMUNOLOGY (2020)
Glutamate Receptors and Glioblastoma Multiforme: An Old Route for New Perspectives
Lorenzo Corsi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Haoxin Li et al.
NATURE COMMUNICATIONS (2019)
Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications
Zixiang Ye et al.
JOURNAL OF CANCER (2019)
Vaccination in the immunotherapy of glioblastoma
Ziren Kong et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
IDO1 in cancer: a Gemini of immune checkpoints
Lijie Zhai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Erik Ladomersky et al.
CLINICAL CANCER RESEARCH (2018)
The Role of indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
Lilla Hornyak et al.
FRONTIERS IN IMMUNOLOGY (2018)
Targeting the IDO1 pathway in cancer: from bench to bedside
Ming Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Andrea Botticelli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Characterization of the Selective lndoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Bruno Gomes et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer
Eric Fox et al.
FRONTIERS IN ONCOLOGY (2018)
Determination of epacadostat, a novel IDO1 inhibitor in mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice
Vinay Dhiman et al.
BIOMEDICAL CHROMATOGRAPHY (2017)
Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions
Petr Tomek et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indo1-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate
Stefano Crosignani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Kynurenine pathway metabolism and neuroinflammatory disease
Nady Braidy et al.
NEURAL REGENERATION RESEARCH (2017)
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (ID01) Inhibitor for Immunooncology
Eddy W. Yue et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas
Mery Stefani Leivas Pereira et al.
ONCOTARGET (2017)
Discovery of IDO1 Inhibitors: From Bench to Bedside
George C. Prendergast et al.
CANCER RESEARCH (2017)
Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival
Lijie Zhai et al.
CLINICAL CANCER RESEARCH (2017)
Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects
Abdulla A-B Badawy
INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH (2017)
Understanding the role of the kynurenine pathway in human breast cancer immunobiology
Benjamin Heng et al.
ONCOTARGET (2016)
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
David A. Reardon et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Analysis of Kynurenine/Tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients
Jayakumar Hascitha et al.
CLINICAL BIOCHEMISTRY (2016)
Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
Jon Bjoern et al.
CYTOTHERAPY (2016)
Novel vaccines for glioblastoma: clinical update and perspective
Evan K. Winograd et al.
IMMUNOTHERAPY (2016)
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
Caroline Jochems et al.
ONCOTARGET (2016)
Glioblastoma: Overview of Disease and Treatment
Mary Elizabeth Davis
CLINICAL JOURNAL OF ONCOLOGY NURSING (2016)
Roles of the translation initiation factor eIF2α serine 51 phosphorylation in cancer formation and treatment
Antonis E. Koromilas
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2015)
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Lijie Zhai et al.
CLINICAL CANCER RESEARCH (2015)
The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy
Lijie Zhai et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer
Mads Duus Hjortso et al.
ONCOIMMUNOLOGY (2015)
Predictors of venous thromboembolism in patients with glioblastoma multiforme.
Shahzaib Nabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Epidemiologic and Molecular Prognostic Review of Glioblastoma
Jigisha P. Thakkar et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2014)
Involvement of the Kynurenine Pathway in Human Glioma Pathophysiology
Seray Adams et al.
PLOS ONE (2014)
Kynurenic acid inhibits proliferation and migration of human glioblastoma T98G cells
Katarzyna Walczak et al.
PHARMACOLOGICAL REPORTS (2014)
Kynurenines in CNS disease: regulation by inflammatory cytokines
Brian M. Campbell et al.
FRONTIERS IN NEUROSCIENCE (2014)
AhR-mediated, non-genomic modulation of IDO1 function
Maria Teresa Pallotta et al.
FRONTIERS IN IMMUNOLOGY (2014)
The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress
Felix Sahm et al.
CANCER RESEARCH (2013)
Kynurenine 3-monooxygenase mediates inhibition of Th17 differentiation via catabolism of endogenous aryl hydrocarbon receptor ligands
Geoffrey L. Stephens et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Aryl hydrocarbon receptor signaling regulates NF-κB RelB activation during dendritic-cell differentiation
Christoph F. A. Vogel et al.
IMMUNOLOGY AND CELL BIOLOGY (2013)
Quinolinic Acid: An Endogenous Neurotoxin with Multiple Targets
Rafael Lugo-Huitron et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2013)
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2013)
The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase
Mads Hald Andersen
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Michael Platten et al.
CANCER RESEARCH (2012)
IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2012)
Development and validation of a single analytical method for the determination of tryptophan, and its kynurenine metabolites in rat plasma
Marisa Moeller et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2012)
The kynurenine system and immunoregulation
Yvette Mandi et al.
JOURNAL OF NEURAL TRANSMISSION (2012)
Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery
Flavio Moroni et al.
JOURNAL OF NEURAL TRANSMISSION (2012)
Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase
Shamaila Munir et al.
PLOS ONE (2012)
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR A novel IDO effector pathway targeted by D-1-methyl-tryptophan
Richard Metz et al.
ONCOIMMUNOLOGY (2012)
Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats
Nady Braidy et al.
FEBS JOURNAL (2011)
CANCER Why tumours eat tryptophan
George C. Prendergast
NATURE (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Ren-Yuan Bai et al.
NEURO-ONCOLOGY (2011)
On the antioxidant properties of kynurenic acid: Free radical scavenging activity and inhibition of oxidative stress
R. Lugo-Huitron et al.
NEUROTOXICOLOGY AND TERATOLOGY (2011)
The Involvement of Neuroinflammation and Kynurenine Pathway in Parkinson's Disease
Anna Zinger et al.
PARKINSONS DISEASE (2011)
Kynurenine and its metabolites in Alzheimer's disease patients
E. Gulaj et al.
ADVANCES IN MEDICAL SCIENCES (2010)
Tumor Antigen Epitopes Interpreted by the Immune System as Self or Abnormal-Self Differentially Affect Cancer Vaccine Responses
Sean O. Ryan et al.
CANCER RESEARCH (2010)
CD11c(+)CD8(+) T cells: Two-faced adaptive immune regulators
Dass S. Vinay et al.
CELLULAR IMMUNOLOGY (2010)
Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats
Paula Pierozan et al.
EXPERIMENTAL NEUROLOGY (2010)
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Joshua D. Mezrich et al.
JOURNAL OF IMMUNOLOGY (2010)
Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct
Johan Soderlund et al.
JOURNAL OF NEUROINFLAMMATION (2010)
Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase
Silvia K. Schmidt et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway
Helen J. Ball et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons
Abdur Rahman et al.
PLOS ONE (2009)
The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
Rikke Baek Sorensen et al.
PLOS ONE (2009)
A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase
T. Banerjee et al.
ONCOGENE (2008)
AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth
Andrzej Stepulak et al.
CANCER BIOLOGY & THERAPY (2007)
Characterization of the kynurenine pathway in human neurons
Gilles J. Guillemin et al.
JOURNAL OF NEUROSCIENCE (2007)
Autocrine glutamate signaling promotes glioma cell invasion
Susan A. Lyons et al.
CANCER RESEARCH (2007)
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase
Madhav D. Sharma et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
David H. Munn et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Tissue expression and biochemical characterization of human 2-amino 3-carboxymuconate 6-semialdehyde decarboxylase, a key enzyme in tryptophan catabolism
Lisa Pucci et al.
FEBS JOURNAL (2007)
NAD(+) and NADH in brain functions, brain diseases and brain aging
Weihai Ying
FRONTIERS IN BIOSCIENCE-LANDMARK (2007)
Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats
Cesar A. J. Ribeiro et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Kynurenic acid has a dual action on AMPA receptor responses
Christina Prescott et al.
NEUROSCIENCE LETTERS (2006)
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:: Effect on tumor-infiltrating T cells
G Brandacher et al.
CLINICAL CANCER RESEARCH (2006)
NMDA antagonist inhibits the extracellular signal-reglulated kinase pathway and suppresses cancer growth
A Stepulak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro
C Di Serio et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2005)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
DH Munn et al.
IMMUNITY (2005)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
IDO expression by dendritic cells: Tolerance and tryptophan catabolism
AL Mellor et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
MIP-1α and MIP-1β differentially mediate mucosal and systemic adaptive immunity
JW Lillard et al.
BLOOD (2003)
T cell apoptosis by tryptophan catabolism
I Fallarino et al.
CELL DEATH AND DIFFERENTIATION (2002)
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase
DH Munn et al.
SCIENCE (2002)
Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy
U Keilholz et al.
JOURNAL OF IMMUNOTHERAPY (2002)
Increased cortical kynurenate content in schizophrenia
R Schwarcz et al.
BIOLOGICAL PSYCHIATRY (2001)
Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid
A Chiarugi et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Glutamate antagonists limit tumor growth
W Rzeski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1α and-1β in macrophages
MC Bosco et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
